Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902681 | 1.00 | ROCK1 (0.43) | ROCK1ROCK2KDM5AHTR3APARP1 | |
| SCHEMBL17452567 | 0.89 | ROCK2 (0.53) | ROCK1ROCK2KDM5AHTR3APARP1 | |
| SCHEMBL19902332 | 0.87 | ROCK1 (0.43) | ROCK1ROCK2KDM5APARP1NPC1 | |
| SCHEMBL19902341 | 0.87 | ROCK1 (0.43) | ROCK1ROCK2KDM5APARP1NPC1 | |
| SCHEMBL19902639 | 0.77 | KDM4E (0.51) | ROCK2NPC1RAB9A | |
| SCHEMBL17452566 | 0.76 | ROCK2 (0.53) | ROCK1ROCK2KDM5AHTR3APARP1 | |
| SCHEMBL17438040 | 0.76 | ROCK2 (0.53) | ROCK1ROCK2KDM5AHTR3APARP1 | |
| SCHEMBL19902644 | 0.75 | ROCK1 (0.56) | ROCK1ROCK2NPC1RAB9A | |
| SCHEMBL19902631 | 0.74 | HDAC8 (0.42) | ROCK1ROCK2PARP1NPC1RAB9A | |
| SCHEMBL15882169 | 0.74 | ROCK1 (0.77) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885ROCK2 3/4885KDM5A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.